PS
Paul W. Sperduto
Highly rated in
18
conditions

Dr. Paul W. Sperduto

Ridgeview Regional Radiation Oncology
Waconia, MN
Highly rated in
18
conditions
Specialties:Radiation Oncology
Experience:39 Years
Clinical Trials:Currently Recruiting for 5 Trials
Accepts:New Patients
Highly rated in
18
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Paul W. Sperduto's experience treating your condition:
About Dr. Paul W. Sperduto

Paul Sperduto is a Radiation Oncologist in Waconia, Minnesota. Sperduto has been practicing medicine for over 39 years and is highly rated in 18 conditions, according to our data. His top areas of expertise are Metastatic Brain Tumor, Lung Cancer, Lung Adenocarcinoma, Gamma Knife Radiosurgery, and Prostatectomy. He is licensed to treat patients in Minnesota. Sperduto is currently accepting new patients.

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 21 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Paul W. Sperduto it is best to call his office and ask if your insurance is accepted.

Dr. Paul W. Sperduto accepts the following insurance:

  •  Ambetter
  •  Medica
Call to see if your plan is accepted.
Locations
560 S Maple St, Suite 10, Waconia, MN 55387
Background & Education
Graduate Institution
Duke University School Of Medicine, 1984
Specialties
Radiation Oncology
Licenses
Radiology in MN
Hospital Affiliations
Regions Hospital
Ridgeview Medical Center
Abbott Northwestern Hospital
Languages Spoken
English
Chinese
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Recruiting
Publish Date: November 25, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Abiraterone acetateApalutamideHormone therapyPrednisone
Study Phase: Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Other, Drug, Radiation, Biological
Study Drugs: AtezolizumabCetuximabCisplatinDocetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Recruiting
Publish Date: October 27, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: CisplatinFluorouracilGemcitabine HydrochloridePaclitaxel
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Enrollment Status: Recruiting
Publish Date: November 25, 2022
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: CarboplatinPaclitaxelFOLFOX regimenCAPOX regimenDocetaxel5FU
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Recruiting
Publish Date: December 07, 2022
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: AtezolizumabCarboplatinCisplatinEtoposide
Study Phase: Phase 2/Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active, not recruiting
Publish Date: November 25, 2022
Intervention Type: Radiation
Study Phase: Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Active, not recruiting
Publish Date: September 21, 2022
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active, not recruiting
Publish Date: April 08, 2022
Intervention Type: Radiation
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 27, 2022
Intervention Type: Radiation, Biological
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: CapecitabineChemotherapyErlotinib hydrochlorideFluorouracilGemcitabine hydrochloride
Study Phase: Phase 3
A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases
Enrollment Status: Terminated
Publish Date: March 09, 2018
Intervention Type: Drug, Radiation
Study Phase: Phase 3
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active, not recruiting
Publish Date: September 13, 2022
Intervention Type: Drug, Other, Radiation
Study Drugs: BicalutamideDocetaxelFlutamideGoserelin acetateLeuprolide acetateNilutamide
Study Phase: Phase 2/Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Suspended
Publish Date: July 11, 2022
Intervention Type: Radiation, Drug
Study Drugs: DocetaxelGemcitabinePemetrexed DisodiumErlotinib HydrochloridePembrolizumab
Study Phase: Phase 2
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: December 11, 2018
Intervention Type: Radiation
Study Phase: Phase 2
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Enrollment Status: Completed
Publish Date: July 21, 2022
Intervention Type: Other, Radiation, Drug
Study Drug: Lapatinib Ditosylate
Study Phase: Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Active, not recruiting
Publish Date: November 21, 2022
Intervention Type: Radiation, Other, Procedure
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active, not recruiting
Publish Date: September 07, 2022
Intervention Type: Other, Biological, Radiation
Study Drugs: CetuximabDurvalumab
Study Phase: Phase 2/Phase 3
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Enrollment Status: Active, not recruiting
Publish Date: March 11, 2022
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
View 16 Less Clinical Trials -
52 Total Publications
Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
Journal: International journal of radiation oncology, biology, physics
Published: December 06, 2021
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
ST
Dr. Stephanie A. Terezakis
Radiation Oncology | Radiology
Highly rated in
16
conditions
Radiation Oncology
Radiology

M Health Fairview

Radiation Oncology Clinic University Of Minnesota Medical Center

500 Se Harvard St, 
Minneapolis, MN 
 28.9 mi

Stephanie Terezakis is a Radiation Oncologist and a Radiologist in Minneapolis, Minnesota. Terezakis has been practicing medicine for over 19 years and is highly rated in 16 conditions, according to our data. Her top areas of expertise are Hodgkin Lymphoma, Adult Soft Tissue Sarcoma, Classical Hodgkin Lymphoma, Epithelioid Sarcoma, and Gamma Knife Radiosurgery. She is licensed to treat patients in Maryland, Minnesota, and New York. Terezakis is currently accepting new patients.

JC
Dr. Janel A. Cox
Radiation Oncology
Highly rated in
12
conditions
Radiation Oncology

HealthPartners

Regions Hospital

640 Jackson St, 
Saint Paul, MN 
 35.0 mi

Janel Cox is a Radiation Oncologist in Saint Paul, Minnesota. Cox has been practicing medicine for over 34 years and is highly rated in 12 conditions, according to our data. Her top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Lung Cancer, Pleuropulmonary Blastoma, and Lung Adenocarcinoma. She is licensed to treat patients in Minnesota. Cox is currently accepting new patients.

XW
Dr. Xin Wang
Radiation Oncology
Highly rated in
12
conditions
Radiation Oncology

M Health Fairview

Healtheast Medical Research Institute

Minneapolis, MN 
 28.8 mi

Xin Wang is a Radiation Oncologist in Minneapolis, Minnesota. Wang has been practicing medicine for over 41 years and is highly rated in 12 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Familial Prostate Cancer, Glioma, and Atypical Teratoid Rhabdoid Tumor (ATRT). He is licensed to treat patients in Minnesota. Wang is currently accepting new patients.